Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Codeine phosphate; Paracetamol
Bayer Plc
N02AJ06
Codeine phosphate; Paracetamol
8mg ; 500mg
Effervescent tablet
Oral
Schedule 5 (CD Inv)
Valid as a prescribable product
BNF: 04070100; GTIN: 5010605188220
OBJECT 1 PARACODOL TABLETS Summary of Product Characteristics Updated 27-Feb-2018 | Bayer plc 1. Name of the medicinal product Paracodol tablets 2. Qualitative and quantitative composition Each soluble tablet contains: Paracetamol DC 520.0 mg (equivalent to paracetamol 500.0 mg) Codeine Phosphate Hemihydrate 8.0 mg For a full list of excipients see section 6.1 3. Pharmaceutical form Soluble Tablet 4. Clinical particulars 4.1 Therapeutic indications Paracodol Tablets (which contain codeine) are indicated in patients older than 12 years of age for the short term treatment of acute moderate pain (such as muscular and rheumatic pains, headache, migraine, neuralgia, toothache, period pains, aches and pains) which is not considered to be relieved by other analgesics such as paracetamol, ibuprofen or aspirin alone. 4.2 Posology and method of administration Posology: Tablets are to be dissolved in water before oral administration. Adults: 1 - 2 tablets, which may be repeated every four to six hours with a maximum of 8 tablets in 24 hours. Elderly: No current evidence for the alteration of the adult dose except where there is impaired hepatic function when dosage reduction may be necessary. Children aged 12 - 18 years: 1 tablet, which may be repeated every four to six hours with a maximum of 4 tablets in 24 hours. Children under 12 years: Paracodol Tablets (which contains Codeine) should not be used in children under 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine (see sections 4.3 and 4.4). The duration of treatment should be limited to 3 days and if no effective pain relief is achieved the patients/carers should be advised to seek the views of a physician. 4.3 Contraindications • Hypersensitivity to paracetamol and/or other constituents. • In women during breastfeeding (see section 4.6) • In patients for whom it is known they are CYP2D6 ultra-rapid metabolisers. • In all paediatric patients (0-18 years of age) who undergo tonsillectomy and/o Read the complete document